By Josh White
Date: Monday 31 Mar 2025
(Sharecast News) - Bioventix reported a marginal rise in revenue for the six months ended 31 December on Monday, with profit before tax dipping slightly due to higher research and development expenditure.
By Iain Gilbert
Date: Thursday 31 Oct 2024
(Sharecast News) - Bioventix revealed on Thursday that chief financial officer Bruce Hiscock had acquired 333 ordinary shares in the London-listed antibodies development and supply company.
By Josh White
Date: Monday 28 Oct 2024
(Sharecast News) - BioVentix, a UK-based developer of high-affinity monoclonal antibodies for clinical diagnostics, reported a 6% improvement in full-year revenue on Monday, to £13.6m, up from £12.82m in the prior year.
| Currency | UK Pounds |
| Share Price | 2,325.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 3,950.00p |
| 52 Week Low | 2,266.00p |
| Volume | 1,828 |
| Shares Issued | 5.22m |
| Market Cap | £121.48m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| 1st Interim | 2nd Interim | |
| Ex-Div | 10-Apr-25 | 07-Nov-24 |
| Paid | 25-Apr-25 | 21-Nov-24 |
| Amount | 70.00p | 87.00p |
| Time | Volume / Share Price |
| 14:34 | 1 @ 2,272.00p |
| 14:24 | 212 @ 2,348.00p |
| 14:08 | 8 @ 2,348.00p |
| 14:06 | 1 @ 2,272.00p |
| 13:53 | 1 @ 2,272.00p |
| CEO | Peter John Harrison |
| Chair | Ian James Nicholson |
| CFO | Bruce Hiscock |
You are here: research